Forge Therapeutics Announces Participation In Upcoming Scientific And Industry Events

SAN DIEGO, Calif., Oct. 24, 2017 /PRNewswire/ -- Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and industry events over the next quarter.  Details of the events are listed below.

Event: SAN DIEGO INNOVATION SHOWCASE

Date: October 26, 2017

Location: Hilton La Jolla Torrey Pines, La Jolla, CA

Presentation Title: Forging New Chemistry Platforms for Generating Novel Medicines

Event: KEYSTONE SYMPOSIA ON ANTIMICROBIALS AND RESISTANCE 

Date: October 29-November 2, 2017

Location:  Eldorado Hotel & Spa, Santa Fe, New Mexico

Poster and Oral Presentation Title: Activity of non-hydroxamate LpxC inhibitors against Acinetobacter baumannii

Event: NEW VENTURE MODELS FOR BIOTECH

Date: November 2, 2017

Location:  The Alexandria at Torrey Pines, San Diego, CA

Panel Title: Biotech Breakouts: Emerging Luminaries of San Diego

Event: BARDA'S INDUSTRY DAY

Date: November 7-8, 2017

Location: Washington D.C.

Panel Title: Powered by CARB-X, How CARB-X is Accelerating Antibacterial Innovation

Event: SUPERBUGS & SUPERDRUGS

Date: November 13-14, 2017

Location: Renaissance Woodbridge Hotel, Iselin, New Jersey

Presentation Title: Forging Ahead with a New Class of Antibiotics

About Forge Therapeutics

At Forge Therapeutics, we are developing medicines targeting metal-dependent enzymes found in nature.  Over 30% of known enzymes are metalloenzymes covering all major enzymes classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases.  Metal ions, including magnesium, zinc, iron, manganese, calcium, cobalt, and copper are the essential ingredient in these metalloenzymes.  At Forge, we are the blacksmiths of modern medicine, providing the tools to address any metalloenzyme challenge.

Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow.  Forge has a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards including CARB-X.  In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its BLACKSMITH platform and pipeline including technology licensed from UCSD. For further information, please visit the company's website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:
[email protected]

Forge Media Contact:
Amy Conrad
Juniper Point
[email protected]
858-366-3243

SOURCE Forge Therapeutics, Inc.

Related Links

http://www.forgetherapeutics.com